Τίτλος:
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
In ENDEAVOR, carfilzomib and dexamethasone (Kd56) demonstrated significant improvement in progression-free survival (PFS) compared with bortezomib and dexamethasone (Vd). Both agents were administered until disease progression; the EU label for Vd, however, stipulates a maximum of eight treatment cycles. Here, matching-adjusted treatment comparison was used to compare efficacy of Kd56 with Vd, if Vd was administered for 8 cycles (Vd-8). Data from ENDEAVOR and CASTOR trials (which compared daratumumab, bortezomib, and dexamethasone with Vd-8) were used. Hazard ratios of PFS were estimated for Vd vs. Vd-8 and Kd vs. Vd-8. For cycles 1–8, risk reduction in PFS for Kd56 vs. Vd-8 was equal to that estimated in ENDEAVOR (HR: 0.53; 95% CI 0.44–0.65). Beyond eight cycles, risk reduction in PFS for Kd56 and Vd-8 was estimated to be 60% (HR: 0.40; 95% CI 0.26–0.63). The analysis suggested that PFS benefit of Kd56 over Vd increases when Vd is given for eight cycles only. © 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Συγγραφείς:
Weisel, K.
Majer, I.
DeCosta, L.
Oriol, A.
Goldschmidt, H.
Ludwig, H.
Campioni, M.
Szabo, Z.
Dimopoulos, M.
Περιοδικό:
Clinical Lymphoma Myeloma and Leukemia
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
bortezomib; carfilzomib; daratumumab; dexamethasone; antineoplastic agent; bortezomib; carfilzomib; dexamethasone; oligopeptide, adult; aged; Article; cancer combination chemotherapy; cancer recurrence; cancer survival; clinical article; comparative effectiveness; comparative study; constipation; diarrhea; drug efficacy; drug safety; embolism; female; heart failure; human; hypertension; male; multiple cycle treatment; multiple myeloma; nausea; peripheral neuropathy; phase 3 clinical trial (topic); priority journal; progression free survival; risk reduction; thrombosis; vomiting; drug resistance; treatment outcome, Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Oligopeptides; Treatment Outcome
DOI:
10.1080/10428194.2019.1648806
